RPA 14 kDa subunit Activators

The RPA 14 kDa subunit, encoded by the RPA3 gene, plays a crucial role in DNA repair and replication processes, with its activity being modulated by various chemical inhibitors and DNA-damaging agents. Inhibitors targeting key kinases involved in DNA damage response, such as VE 821, NU 7441, ATM Kinase Inhibitor, and Roscovitine, lead to increased DNA damage or replication stress. This, in turn, enhances the recruitment and functional activity of the RPA 14 kDa subunit in DNA repair pathways. Specifically, inhibition of ATR and ATM kinases escalates the need for effective DNA repair mechanisms, thereby augmenting the role of RPA 14 kDa subunit in these processes. The inhibition of DNA-PKcs and cyclin-dependent kinases similarly increases the dependency on RPA 14 kDa subunit for maintaining genome stability during replication and repair.

Moreover, the RPA 14 kDa subunit's activity is influenced by various DNA-damaging agents, including Topotecan, Olaparib, 2'-Deoxy-2',2'-difluorocytidine, Hydroxyurea, Etoposide (VP-16), Aphidicolin, Cisplatin, and Mitomycin C. These agents induce different forms of DNA damage, such as double-strand breaks, crosslinks, and replication stress, necessitating the involvement of RPA 14 kDa subunit in the DNA repair mechanisms. For instance, Topotecan and Etoposide (VP-16) induce DNA breaks, while Cisplatin and Mitomycin C cause crosslinking, thereby increasing the recruitment and activity of the RPA 14 kDa subunit. Olaparib's inhibition of PARP enhances the role of RPA 14 kDa subunit in homologous recombination, a key pathway for repairing DNA damage. Collectively, these compounds, through their targeted effects on DNA integrity and replication, underscore the essential role of the RPA 14 kDa subunit in maintaining genomic stability.